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Abstract
Purpose Patients with HER2-positive metastatic breast cancer (MBC) usually receive many years of trastuzumab treatment. 
It is unknown whether these patients require continuous left ventricular ejection fraction (LVEF) monitoring. We studied a 
real-world cohort to identify risk factors for cardiotoxicity to select patients in whom LVEF monitoring could be omitted.
Methods We included patients with HER2-positive MBC who received > 1 cycle of trastuzumab-based therapy in eight 
Dutch hospitals between 2000 and 2014. Cardiotoxicity was defined as LVEF < 50% that declined > 10%-points and was 
categorized into non-severe cardiotoxicity (LVEF 40–50%) and severe cardiotoxicity (LVEF < 40%). Multivariable Cox and 
mixed model analyses were performed to identify risk factors associated with cardiotoxicity. Additionally, we explored the 
reversibility of cardiotoxicity in patients who continued trastuzumab.
Results In total, 429 patients were included. Median follow-up for cardiotoxicity was 15 months (interquartile range 
8–31 months). The yearly incidence of non-severe + severe cardiotoxicity in the first and second year was 11.7% and 9.1%, 
respectively, which decreased thereafter. The yearly incidence of severe cardiotoxicity was low (2.8%) and stable over time. 
In non-smoking patients with baseline LVEF > 60% and no cardiotoxicity during prior neoadjuvant/adjuvant treatment, the 
cumulative incidence of severe cardiotoxicity was 3.1% after 4 years of trastuzumab. Despite continuing trastuzumab, LVEF 
decline was reversible in 56% of patients with non-severe cardiotoxicity and in 33% with severe cardiotoxicity.
Conclusions Serial cardiac monitoring can be safely omitted in non-smoking patients with baseline LVEF > 60% and without 
cardiotoxicity during prior neoadjuvant/adjuvant treatment.
Keywords HER2-positive metastatic breast cancer · Trastuzumab treatment · Cardiotoxicity · LVEF monitoring · Screening 
for cardiotoxicity
Introduction
Trastuzumab is a monoclonal antibody targeting the human 
epidermal growth factor receptor 2 (HER2) that has greatly 
improved the outcome of patients with HER2-positive breast 
cancer in both the primary and metastatic setting [1–3]. 
Trastuzumab toxicity is generally mild, although left ven-
tricle ejection fraction (LVEF) decline (cardiotoxicity) is 
a well-known side effect that is mostly seen in combina-
tion with concurrent or sequential anthracycline treatment 
[3]. Regular LVEF monitoring at a 3-monthly interval is 
therefore recommended during 1 year of neoadjuvant and/or 
adjuvant trastuzumab treatment; however, during metastatic 
treatment no specific time interval of LVEF monitoring is 
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recommended [4]. Since the median overall survival of 
patients with HER2-positive metastatic breast cancer (MBC) 
is well over 4 years with continuous use of trastuzumab, the 
cumulative burden of LVEF monitoring can be high [5, 6]. 
The incidence of cardiotoxicity during long-term treatment 
for HER2-positive MBC, however, is not well-known and 
neither are risk factors for trastuzumab-associated cardio-
toxicity in this setting.
Two studies investigated cardiotoxicity over time dur-
ing trastuzumab treatment in patients with MBC [7, 8]. The 
first study found a cumulative incidence of cardiotoxicity 
of 12.7% and 28.5% after 1 and 3 years of trastuzumab 
use, respectively [7]. They defined cardiotoxicity as  LVEF 
decline  > 20%-points from baseline or LVEF < 50% or 
symptoms of congestive heart failure. The LVEF recovered 
in a vast majority of the patients (84%) after discontinua-
tion of trastuzumab with or without cardio-protective treat-
ment. However, reversibility of cardiotoxicity after continu-
ation of trastuzumab has not been described yet. A second 
study observed a cumulative incidence of cardiotoxicity of 
5.3% after 3 years of trastuzumab use. However, they used 
a composite endpoint that included myocardial ischaemia, 
heart failure, rhythm disorder, and other cardiac diseases 
[8]. Data on long-term sequelae were not available. Lastly, 
risk factors for developing cardiotoxicity during long-term 
trastuzumab treatment could be similar to those causing car-
diotoxicity during 1 year of trastuzumab treatment [9–11]; 
however, this has not been investigated yet.
Therefore, we studied cardiotoxicity during long-term 
trastuzumab treatment in patients with HER2-positive MBC 
in an observational historic multicentre cohort study and 
risk factors associated with cardiotoxicity in this setting to 
select patients in whom LVEF monitoring could be omitted. 
Additionally, we evaluated the reversibility of cardiotoxicity 
in patients who continued trastuzumab.
Methods
Patients and data collection
We included patients with HER2-positive MBC who 
received > 1 cycle of trastuzumab-based treatment in one of 
eight participating Dutch hospitals between January 2000 
and December 2014, as described before [12]. Patients were 
identified using the Netherlands Cancer Registry. Patients 
were excluded in case no baseline LVEF measurement 
was available within 30 days before the first trastuzumab 
administration for MBC, baseline LVEF < 50%, no follow-
up LVEF measurements were available during trastuzumab 
use, and in case of incomplete clinical data in the medical 
records.
Trained investigators systematically retrieved data on 
patient and tumour characteristics, treatment, and LVEF 
measurements from medical records. Medical Ethics Com-
mission of all participating hospitals approved this compre-
hensive data collection.
Endpoints
We defined non-severe + severe cardiotoxicity and severe 
cardiotoxicity based on guidelines of the European Soci-
ety of Cardiology (ESC) [13] and the European Society 
of Medical Oncology (ESMO) [4], respectively. First, 
non-severe + severe cardiotoxicity is defined as (1) LVEF 
decline > 10%-points from baseline and LVEF < 50% meas-
ured with multigated acquisition (MUGA) scan or (2) 
decline from good/normal cardiac function to at least mild 
cardiac dysfunction and at least mild cardiac dysfunction 
measured with echocardiography if MUGA was not avail-
able. After a decline in LVEF found with MUGA scan, in 
some cases this was followed by an echocardiography to 
exclude false negative low LVEF measurements. In case 
both investigations were performed, echocardiography was 
used to define cardiotoxicity. Second, severe cardiotoxicity 
is defined as (1) LVEF < 40% measured with MUGA scan 
or (2) moderate or severe cardiac dysfunction measured 
with echocardiography if MUGA was not available [13]. 
Since patients with LVEF < 50% at baseline were excluded, 
patients with LVEF < 40% had by definition a LVEF decline 
of > 10%-points compared to baseline. Lastly, non-severe 
cardiotoxicity was defined as (1) LVEF < 50% but > 40% 
or mild cardiac dysfunction measured with echocardiog-
raphy. The time to non-severe + severe cardiotoxicity, non-
severe cardiotoxicity or severe cardiotoxicity was calculated 
from start of trastuzumab treatment for MBC to the first 
occurrence of non-severe + severe cardiotoxicity.
For the analyses of reversibility, non-severe + severe 
cardiotoxicity was categorized into non-severe cardiotox-
icity and severe cardiotoxicity. Reversibility of cardiotox-
icity was defined as any LVEF increase to a value < 5% 
below baseline, partially reversibility as any absolute LVEF 
increase ≥ 10% from nadir and to a value > 5% below base-
line, and irreversibility as any absolute LVEF increase < 10% 
from nadir and to a value > 5% below baseline [14]. The 
frequency of LVEF measurements was determined by the 
treating physician.
Statistical analyses
Continuous variables are presented as medians with inter-
quartile range (IQR) for non-normal distribution, and as 
means with standard deviations for normal distribution. 
Categorical variables are presented as percentages.
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Median follow-up for cardiotoxicity was calculated from 
start of trastuzumab for MBC until 6 months after last tras-
tuzumab dose or until last LVEF measurement, whichever 
came first. Discontinuation of trastuzumab treatment was 
defined as any stop or interruption of trastuzumab treatment. 
The yearly incidence of cardiotoxicity was investigated. 
Patients were at risk for cardiotoxicity when receiving LVEF 
measurements during trastuzumab treatment. After the first 
development of non-severe cardiotoxicity, patients were no 
longer at risk for non-severe cardiotoxicity. However, these 
patients were still at risk for severe cardiotoxicity. After 
developing severe cardiotoxicity, patients were no longer at 
risk for any type of cardiotoxicity.
We used univariable and multivariable Cox proportional 
hazards (PH) analyses to determine which baseline variables 
were associated with non-severe + severe cardiotoxicity and 
severe cardiotoxicity, and to find a group of patients at low 
risk of cardiotoxicity. All variables were determined at start 
of trastuzumab treatment for MBC. Independent variables 
statistically significant at 0.10 level in univariable analysis 
or known risk factors for cardiotoxicity from literature were 
included in the multivariable analysis. The Cox PH assump-
tion was verified using the Schoenfeld residuals test and was 
not violated. Multivariable cause-specific Cox PH models 
were built with similar variables to investigate potential 
competing risk from death with non-severe + severe cardio-
toxicity or severe cardiotoxicity. In this analysis, patients are 
censored in case of death due to any cause.
The following variables were included in the analyses: 
age, BMI, hypertension, diabetes mellitus, smoking, history 
of cardiac disease, baseline LVEF < 60%, cardiotoxicity dur-
ing prior neoadjuvant/adjuvant treatment with trastuzumab 
and/or anthracycline, prior cumulative anthracycline expo-
sure, radiation exposure to the breast. BMI was categorized 
in BMI < 25 kg/m2, 25–30 kg/m2, and > 30 kg/m2. Hyper-
tension was defined as a history of systolic blood pres-
sure > 130 mmHg or diastolic blood pressure > 80 mmHg 
or the use of antihypertensive medication [15]. History of 
cardiac disease was defined as the history of either arrhyth-
mia, cardiac valve deficiency, cardiomyopathy or coronary 
artery disease. Cardiotoxicity during prior treatment was 
defined LVEF decline > 10%-points to a LVEF < 50% dur-
ing neoadjuvant/adjuvant treatment with trastuzumab and/
or anthracycline. Prior cumulative anthracycline exposure 
was defined as the number of courses anthracycline before 
trastuzumab in palliative setting. Radiation exposure was 
categorized in left-sided, right-sided or unknown side. Last, 
de novo metastatic breast cancer was defined as metastatic 
disease at time of diagnosis or development of metastases 
within 3 months of diagnosis.
For the multivariable Cox PH analyses, missing informa-
tion on diabetes mellitus, hypertension, smoking, history of 
cardiac disease, radiotherapy side and cardiotoxicity during 
prior neoadjuvant/adjuvant treatment with trastuzumab and/
or anthracycline was imputed using fully conditional speci-
fication with 100 imputations. Estimates were pooled over 
imputed data sets using Rubin’s rules. A sensitivity analysis 
with a complete case analysis was conducted to investigate 
robustness of the imputation procedure. In the cause-specific 
Cox PH analyses, missing values were imputed using sub-
stantive model compatible fully conditional specification 
with 100 imputations. Additionally, sensitivity analyses were 
performed by investigating the number of LVEF measure-
ments as a risk factor for cardiotoxicity in a Cox PH analysis 
to investigate detection bias. LVEF measurements up until 
the development of cardiotoxicity were taken into account 
in these analyses.
To study the relation between the independent variables 
and continuous LVEF measurements during total follow-
up, linear mixed effects model (LMM) analysis was con-
ducted. Risk factors that are related to a LVEF decline, but 
not with the definition of cardiotoxicity, were investigated 
in this analysis. In addition to the variables used in the Cox 
PH analysis, this model allows to investigate time varying 
variables, namely the cumulative trastuzumab exposure at 
each LVEF measurement calculated from start trastuzumab 
to each LVEF measurement (in months). The fit of the LMM 
was adjusted by the non-linear curve observed from the 
predicted values plot (data not shown) [16]. The effect of 
time since start trastuzumab was modelled using restricted 
cubic splines, with the number of knots (4) chosen using 
information criteria. Random intercept and random slope of 
time since start of trastuzumab were included to account for 
within-patient correlations between repeated measurements.
Inverse Kaplan–Meier curves stratified for significant risk 
factors were used to investigate the cumulative incidence of 
non-severe + severe cardiotoxicity and severe cardiotoxicity 
for the number of significant risk factors from the Cox PH 
analysis.
Data analyses were performed using SPSS (version 24.0) 
and R (version 3.4.3), in particular the packages “lme”, 
“splines”, “JointAI”, “smcfcs” and “mice”.
Results
Patient characteristics
Between January 2000 and December 2014, 745 patients 
with HER2-positive MBC were identified in the eight par-
ticipating Dutch hospitals. After excluding patients who had 
no baseline LVEF measurement (n = 193), a baseline LVEF 
measurement < 50% (n = 41), no LVEF measurement during 
trastuzumab treatment (n = 55), or in whom no additional 
data collection was possible (n = 18), 429 patients were eli-
gible for current analyses (Supplementary Figure S1). In 
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general, no difference was observed between included and 
excluded patients, except for a lower percentage of patients 
receiving prior neoadjuvant/adjuvant trastuzumab in the lat-
ter (Supplementary Table S1). Patient and treatment char-
acteristics are shown in Table 1. Of all patients, 311 (72%) 
had metachronous distant metastases and 118 (28%) had 
synchronous distant metastases at disease presentation.
Patients were followed for cardiotoxicity with a median 
of 15 months (IQR 8–31). The median overall survival for 
all patients was 42 months (IQR 25–71). Median frequency 
of LVEF monitoring was 4 times annually (IQR 3–5) with 
a median total number of LVEF measurements of 4 during 
follow-up (IQR 2–7). Most commonly used cardiac imaging 
modality for LVEF assessment was the MUGA scan in 358 
patients (83%). Echocardiography (4%) or CMR (0.2%) or a 
combination of both (13%) was performed less often.
Incidence of non‑severe + severe and severe 
cardiotoxicity over time
During total follow-up, 94 patients (22%) developed non-
severe + severe cardiotoxicity. In the first year of trastu-
zumab treatment, the incidence of non-severe + severe 
cardiotoxicity was 11.7% (Fig. 1). The yearly incidence 
gradually decreased over the following years (i.e. 9.1% in 
year 2 to 3.6% in year 6). The median time to develop non-
severe + severe cardiotoxicity from start of trastuzumab for 
MBC was 11 months (IQR 5–23).
In total, 25 patients (6%) developed severe cardiotoxicity. 
In the first year of trastuzumab treatment, the incidence of 
severe cardiotoxicity was 2.8% (Fig. 1). The yearly incidence 
of severe cardiotoxicity the next years remained stable (i.e. 
1.9% in year 2 to 2.4% in year 6). The median time to severe 
cardiotoxicity was 10 months (IQR 6–25).
Risk factors associated with non‑severe + severe 
cardiotoxicity and severe cardiotoxicity
Risk factors independently associated with non-
severe + severe cardiotoxicity were BMI > 30  kg/m2 
(adjusted [a]HR 2.16, 95% CI 1.15–4.06), smoking (aHR 
1.73, 95% CI 1.05–2.85), cardiotoxicity during prior neoad-
juvant/adjuvant treatment with trastuzumab and/or anthra-
cyclines (aHR 4.48, 95% CI 1.56–12.87). Prior neoadju-
vant/adjuvant trastuzumab (aHR 0.38, 95% CI 0.18–0.82) 
was associated with less non-severe + severe cardiotoxicity 
(Table 2).
Risk factors independently associated with severe car-
diotoxicity were smoking (aHR 6.15, 95% CI 2.12–17.82), 
baseline LVEF < 60% (aHR 7.64, 95% CI 1.70–34.43) and 
cardiotoxicity during prior neoadjuvant/adjuvant treatment 
with trastuzumab and/or anthracycline (aHR 5.60, 95% CI 
1.03–30.42, Table 3).
Cause-specific Cox PH analyses, taking competing risk 
between cardiotoxicity and death into account, showed simi-
lar risk factors associated with non-severe + severe cardio-
toxicity and severe cardiotoxicity (Supplementary Table S2).
LMM analysis (Table 4) also showed similar risk factors 
that were associated with LVEF differences over time as the 
Cox PH analyses (Tables 2 and 3). This means that patients 
who smoked on average had 2.77%-points lower LVEFs at 
the same time point compared to patients who did not smoke 
(Table 4; p < 0.001).
Cumulative incidence of cardiotoxicity per relevant 
risk factors
The identified significant risk factors from the Cox PH anal-
yses (Tables 2 and 3) were used to identify a patient group at 
low risk for cardiotoxicity, regardless of their effect size. In 
total, 241 patients had no relevant risk factors, 152 patients 
1 risk factor and 36 patients 2 or 3 risk factors. Regarding 
relevant risk factors for severe cardiotoxicity, 242 had no 
risk factors, 158 patients 1 risk factors and 29 patients 2 or 3 
risk factors. Patients without relevant risk factors for severe 
cardiotoxicity had a low cumulative incidence of 3.1% after 
a total follow-up of 4 years (Fig. 2). The cumulative inci-
dence for both non-severe + severe cardiotoxicity and severe 
cardiotoxicity increases in case of more relevant risk factors.
Sensitivity analyses evaluating detection bias 
of cardiotoxicity
Patients who received 0–2 LVEF measurements annually 
had lower risk of non-severe + severe cardiotoxicity and 
severe cardiotoxicity compared to patients who received 
3–4 LVEF measurements annually (HR 0.43, 95% CI 
0.24–0.78), however not of severe cardiotoxicity (HR 0.66, 
95% CI 0.22–1.97). Additionally, patients who received > 4 
LVEF measurements annually had higher risk of non-severe 
+ severe cardiotoxicity (HR 6.39, 95% CI 3.57–11.41) and 
severe cardiotoxicity (HR 3.65, 95% CI 1.38–9.62).
Reversibility of non‑severe + severe cardiotoxicity 
and severe cardiotoxicity
To explore the reversibility of cardiotoxicity, we categorized 
the patients who developed non-severe + severe cardiotoxic-
ity into non-severe cardiotoxicity (n = 69) and severe cardio-
toxicity (n = 25), of whom reversibility could be analysed in 
58 patients with non-severe cardiotoxicity and 16 patients 
with severe cardiotoxicity (Fig. 3).
In total, the LVEF decline was reversible in 34 out of 
58 patients (59%) who developed non-severe cardiotoxicity 
Breast Cancer Research and Treatment 
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Table 1  Baseline characteristics 
of all included patients (n = 429)
IQR interquartile range, LVEF left ventricle ejection fraction, BMI body mass index, MUGA scan, multi-
gated acquisition scan, MRI magnetic resonance imaging, MBC metastatic breast cancer
a At start of palliative trastuzumab treatment; for definition see Methods section
b Estrogen and progesterone receptor positivity was defined as ≥ 10% positive nuclear staining [17]
c Number of courses before palliative trastuzumab treatment
d Could consist of doxorubicin or epirubicin courses
Clinical and treatment characteristics No. (%), median [IQR]
Age (years)a 54 [46–61]






 Anthracyclines + trastuzumab 65 (15)
 Anthracyclines without trastuzumab 120 (28)
 Trastuzumab without anthracyclines 19 (4)
 Other 12 (3)
Duration of neoadjuvant/adjuvant trastuzumab (months) 12 [12–12]
Prior cumulative anthracycline exposure (courses)a,c,d 0 [0–4]
Adjuvant radiotherapy
 No 171 (40)
 Left side 126 (29)
 Right side 100 (23)
 Side unknown 32 (8)





  ≥ 60 198 (46)
  < 60 231 (54)
BMI (kg/m2)a
  < 25 164 (49)
 25–30 130 (30)
  > 30 44 (10)
 Unknown 91 (21)
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(Fig.  3 and Supplementary Figure S2). Among the 15 
patients who discontinued trastuzumab for at least one cycle 
after non-severe cardiotoxicity, 7 patients received LVEF 
measurements. Of those patients, the LVEF was reversible in 
4 patients (57%), partially reversible in 1 patient (14%) and 
irreversible in 2 patients (29%). Of the 43 patients who con-
tinued trastuzumab, 23 (56%) had normalization of LVEF, 
in 6 (15%) the LVEF decline was partially reversible and in 
12 (29%) irreversible. Of all patients developing non-severe 
cardiotoxicity, 23% had cardiac symptoms including short-
ness of breath or angina pectoris. The reversibility was inde-
pendent of the presence of cardiac symptoms.
The LVEF decline was reversible in 6 out of the 16 
patients (35%) who developed severe cardiotoxicity and 
received LVEF measurements (Fig.  3 and Supplemen-
tary Figure S2). Among the 19 patients who discontinued 
trastuzumab after severe cardiotoxicity, the LVEF decline 
was reversible in 4 patients (40%), partially reversible in 3 
patients (30%) and irreversible in 3 patients (30%). Among 
the 6 patients who continued trastuzumab after severe car-
diotoxicity, the LVEF decline was reversible in 2 patients 
(33%), partially reversible in 3 patients (50%) and irrevers-
ible in 1 patient (17%). In the five patients with revers-
ible severe cardiotoxicity, trastuzumab could be continued 
safely without recurring cardiotoxicity for a mean duration 
of 17 months (range 3–35). Of all patients who developed 
severe cardiotoxicity, 72% had cardiac symptoms. The 
reversibility was independent of the presence of cardiac 
symptoms.
Discussion
In this study, we showed that among patients with HER2-
positive MBC the yearly incidence of non-severe + severe 
cardiotoxicity was highest in the first 2 years of trastu-
zumab (11.7% and 9.1%, respectively) and gradually 
decreased over time. The median time to develop non-
severe + severe cardiotoxicity was 11 months. The yearly 
incidence of severe cardiotoxicity was low over time 
(range 1.2–2.8%) with a median time to develop severe 
cardiotoxicity of 10 months. In non-smoking patients with 
Fig. 1  Yearly incidence of 
non-severe + severe cardiotoxic-
ity and severe cardiotoxicity 
during long-term trastuzumab 
treatment
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baseline LVEF > 60% and no cardiotoxicity during prior 
neoadjuvant/adjuvant treatment (i.e. no relevant risk fac-
tors), the cumulative incidence of severe cardiotoxicity 
was limited to 3.1% after 4 years. Physicians often con-
tinued trastuzumab treatment despite cardiotoxicity, i.e. 
62% in case of non-severe cardiotoxicity and 24% in case 
of severe cardiotoxicity. Interestingly, reversibility was 
relatively high among those who continued trastuzumab 
(71% after non-severe cardiotoxicity and 83% after severe 
cardiotoxicity of whom 56% and 33% fully recovered, 
respectively). Taken together, our data show the limited 
clinical relevance of regular cardiac monitoring by LVEF 
measurements in patients without relevant risk factors, 
stressing the need for an alternative monitor schedule.
The incidence of cardiotoxicity observed in this study 
was lower than reported in some other studies investigating 
cardiotoxicity of trastuzumab in the advanced setting [3, 7, 
18]. This might be explained by the fact that these studies 
included patients treated with concomitant and higher doses 
of anthracyclines than our study [3, 18]. In addition, some 
studies used other imaging modalities besides MUGA scan 
and had a less strict criteria to define cardiotoxicity [7, 18].
We aimed to identify subgroups with particular low 
risk of developing cardiotoxicity in order to tailor cardiac 
monitoring. In our study, high BMI, smoking, cardiotoxic-
ity during prior neoadjuvant/adjuvant treatment with tras-
tuzumab and/or anthracyclines and baseline LVEF < 60% 
were found to be statistically significant independent risk 
factors for cardiotoxicity, whereas other cardiovascular risk 
factors were not. This might be due to the fact that our study 
population consisted of relatively young patients (median 
age was 54 years) with a good LVEF (> 50%) before starting 
trastuzumab. In the study of Rossi et al., age was an impor-
tant risk factor for cardiotoxicity among patients receiving 
trastuzumab for HER2-positive MBC [8]. In the study of 
Guarneri et al., baseline LVEF and time from last anthra-
cycline administration were important risk factors [7]. In 
addition, a recent study indicated that polymorphism HER2-
Ile655 A > G is a risk factor for developing cardiotoxicity 
during trastuzumab [19]. Whether this risk factor will help 
Table 2  Risk factors present at start of trastuzumab treatment for MBC associated with developing non-severe + severe cardiotoxicity
PH proportional hazards, HR hazard ratio, CI confidence interval, BMI body mass index, LVEF left ventricle ejection fraction, MBC metastatic 
breast cancer, REF reference category
a Based on multiple imputations with MICE of diabetes mellitus, hypertension, smoking, history of cardiac disease, local radiotherapy of the 
breast and prior cardiotoxicity during treatment with trastuzumab or anthracyclines, where death is a censoring event
b A course consist of doxorubicin 60 mg/m2 or epirubicin 100 mg/m2
Univariable Cox  PHa Multivariable Cox  PHa
HR 95% CI p-value Adjusted HR 95% CI p-value
Age (years) 1.01 0.99–1.02 0.574 1.01 0.99–1.03 0.254
BMI (kg/m2)
  < 25 Ref
 25–30 1.29 0.76–2.17 0.340 1.24 0.73–2.12 0.423
  > 30 2.05 1.13–3.73 0.018 2.16 1.15–4.06 0.017
Hypertension 1.23 0.77–1.95 0.386
Diabetes mellitus 1.20 0.55–2.64 0.651
Smoking 1.89 1.13–3.16 0.016 1.73 1.05–2.85 0.031
History of cardiac disease 1.36 0.71–2.60 0.352
Baseline LVEF (%)
  ≥ 60 Ref
  < 60 1.60 1.05–2.44 0.030 1.52 0.97–2.40 0.071
Prior neoadjuvant/adjuvant trastuzumab 0.60 0.33–1.10 0.097 0.38 0.18–0.82 0.014
Cardiotoxicity during prior neoadjuvant/adjuvant treatment with 
trastuzumab and/or anthracyclines
2.36 1.05–5.30 0.037 4.48 1.56–12.87 0.005
Cumulative anthracycline exposure (total number of courses)b 1.05 0.98–1.14 0.155 1.05 0.97–1.15 0.247
Adjuvant radiotherapy
 No Ref
 Left side 1.01 0.62–1.65 0.977
 Right side 1.00 0.57–1.73 0.987
 Side unknown 1.22 0.57–2.62 0.615
De novo metastatic breast cancer 0.78 0.48–1.26 0.313 0.81 0.47–1.40 0.451
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personalizing cardiac monitoring in patients with HER2-
positive MBC remains to be investigated.
By combining the incidence of cardiotoxicity over time 
with an individual cardiovascular risk profile, a tailored car-
diac monitoring recommendation could be given, in case a 
yearly incidence of severe cardiotoxicity of less than 1%, 
while on average in women aged ≥ 50 in Europe the yearly 
incidence of heart failure ranges between 0.2 and 2.2% 
[20], is considered acceptable. This would result in the fol-
lowing recommendations. First, for patients with a baseline 
LVEF above 60%, without cardiotoxicity during prior neoad-
juvant/adjuvant treatment with trastuzumab and/or anthracy-
cline and who do not smoke, further serial cardiac monitor-
ing during trastuzumab treatment could be omitted, since 
the cumulative incidence of severe cardiotoxicity in these 
patients after 4 years of trastuzumab treatment is low (3.1%). 
Second, for patients with ≥ 1 risk factor, cardiac monitor-
ing during the first 3 years would be recommended as the 
yearly increase and absolute numbers of non-severe + severe 
cardiotoxicity were low after 3 years. Thereafter, cardiac 
monitoring could be performed in case of cardiac symptoms. 
The high reversibility rates of cardiotoxicity in a substantial 
number of patients with MBC, even after continuing trastu-
zumab, support our proposed individualized LVEF monitor-
ing scheme during (long-term) trastuzumab treatment.
We did not have sufficient data on the use or start of car-
dio-protective medication which could be of value in deter-
mining trastuzumab continuation after cardiotoxicity and in 
evaluating the reversibility of cardiotoxicity. Furthermore, 
we could not assess whether the use or start of cardio-protec-
tive medication could be helpful for the proposed individual-
ized LVEF monitoring schemes. Medication, including ACE 
inhibitors (perindopril, lisinopril), beta-blockers (carvedilol, 
bisoprolol) or angiotensin receptor blocker (candesartan), 
has shown to attenuate LVEF declines and thereby poten-
tially increase the reversibility of LVEF declines [21–25].
To the best of our knowledge, this study is the largest in 
number with the longest follow-up duration investigating 
the reversibility of cardiotoxicity during trastuzumab in 
patients with HER2-positive MBC. Although the historical 
Table 3  Risk factors present at start of trastuzumab treatment for MBC associated with developing severe cardiotoxicity
PH proportional hazards, HR hazard ratio, CI confidence interval, BMI body mass index, LVEF left ventricle ejection fraction, MBC metastatic 
breast cancer, REF reference category
a Based on multiple imputations with MICE diabetes mellitus, hypertension, smoking, history of cardiac disease, local radiotherapy of the breast 
and prior cardiotoxicity during treatment with trastuzumab or anthracyclines, where death is a censoring event
b A course consist of doxorubicin 60 mg/m2 or epirubicin 100 mg/m2
Univariable Cox  PHa Multivariable Cox  PHa
HR 95% CI p-value Adjusted HR 95% CI p-value
Age (years) 1.00 0.97–1.04 0.926
BMI (kg/m2)
  < 25 Ref
 25–30 1.02 0.76–2.17 0.975
  > 30 1.99 1.13–3.73 0.188
Hypertension 1.39 0.57–3.35 0.468
Diabetes mellitus 0.65 0.09–4.82 0.673
Smoking 6.61 2.23–19.60  < 0.001 6.15 2.12–17.82  < 0.001
History of cardiac disease 2.61 0.98–6.96 0.056
Baseline LVEF(%)
  ≥ 60 Ref
  < 60 9.91 2.34–42.05 0.002 7.64 1.70–34.43 0.008
Prior neoadjuvant/adjuvant trastuzumab 1.07 0.40–2.87 0.891
Cardiotoxicity during prior neoadjuvant/adjuvant treatment with 
trastuzumab and/or anthracycline
3.30 0.87–12.56 0.079 5.60 1.03–30.42 0.045
Cumulative anthracycline exposure (total number of courses)b 1.21 1.07–1.37 0.003 1.15 1.00–1.33 0.051
Adjuvant radiotherapy
 No Ref
 Left side 1.01 0.41–2.53 0.975
 Right side 0.73 0.23–2.31 0.597
 Unknown side 0.56 0.07–4.34 0.577
De novo metastatic breast cancer 0.46 0.16–1.34 0.153
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observational design of this cohort study provided a valu-
able opportunity to investigate clinical practice, some limi-
tations inherent to historic cohorts should be mentioned. 
First, not all variables could retrospectively be collected 
and therefore not all variables, for example medication use 
and total dose of anthracycline treatment (mg/m2) and radi-
ation treatment (Gy), could be investigated. Although some 
missing data were observed for other variables as well, 
these variables could be used after multiple imputation as 
sensitivity analysis with complete case analysis showed 
similar risk factors associated with non-severe + severe 
cardiotoxicity as after multiple imputations (Supplemen-
tary Table S3). Second, due to the lack of clear cardiac 
monitoring guidelines, the timing of the LVEF measure-
ments was not standardized but chosen by the treating phy-
sician. Therefore, ascertainment of cardiotoxicity could be 
delayed and detection bias cannot be excluded. However, 
information bias cannot have influenced the incidence of 
cardiotoxicity as LVEF measurements after cardiotoxicity 
were not taken into account. Third, most LVEFs (83%) 
were measured by MUGA scanning with a known high 
inter-observer and intra-observer variability in measuring 
the LVEF [26, 27]. However, by using a LMM analysis that 
takes into account all available LVEF measurements, the 
effect of this variability is minimized. Fourth, in estimating 
the cumulative incidence of cardiotoxicity per number of 
relevant risk factors, the effect size of the individual risk 
factors was not taken into account. Fifth, as the primary 
endpoint of the study was the development of cardiotoxic-
ity, we did not investigate other cardiac co-morbidities that 
could develop over time. In addition, due to the median fol-
low-up of the study of 15 months, we were unable to assess 
this. Last, only 26 patients (6%) in our cohort received dual 
HER2-targeted therapy, which is the current standard of 
first-line treatment for patients with HER2-positive MBC. 
However, as pertuzumab does not increases the risk of car-
diotoxicity [28], the results of this study are likely to be 
applicable to daily clinical practice.
Table 4  Risk factors present at start of trastuzumab for MBC associated with continuous LVEF differences at each time point during total fol-
low-up
LVEF left ventricle ejection fraction, CI credible interval, BMI body mass index, MBC metastatic breast cancer, REF reference category
a Based on multiple imputations with MICE of diabetes mellitus, hypertension, smoking, history of cardiac disease, local radiotherapy of the 
breast and prior cardiotoxicity during treatment with trastuzumab or anthracyclines
b From start of palliative trastuzumab treatment to each LVEF measurement
c A course consist of doxorubicin 60 mg/m2 or epirubicin 100 mg/m2
Estimated absolute LVEF differ-
ence at each time point (%)a
95% CI Tail-probability
Cumulative trastuzumab exposure (months)b 0.27 − 0.06 to 0.51 0.163
Age (years) 0.02 − 0.05 to 0.09 0.642
BMI (kg/m2)
  < 25 Ref
 25–30 − 1.04 − 2.90 to 0.73 0.237
  > 30 − 1.09 − 3.44 to 1.30 0.389
Hypertension 0.67 − 1.13 to 2.47 0.461
Diabetes mellitus − 0.71 − 3.62 to 2.14 0.624
Smoking − 2.77 − 5.26 to − 0.66 0.013
History of cardiac disease 0.40 − 2.21 to 3.04 0.766
Baseline LVEF (%)
  ≥ 60 Ref
  < 60 − 6.72 − 8.17 to − 5.28  < 0.001
Prior neoadjuvant/adjuvant trastuzumab 2.11 − 0.09 to 4.31 0.060
Cardiotoxicity during prior neoadjuvant/adjuvant treatment with 
trastuzumab and/or anthracyclines
− 13.70 − 22.64 to − 5.45  < 0.001
Cumulative anthracycline exposure (total number of courses)c − 0.38 − 0.69 to 0.08 0.012
Adjuvant radiotherapy
 No Ref
 Left side 0.20 − 1.61 to 2.02 0.827
 Right side 0.44 − 1.54 to 2.43 0.662
 Side unknown 1.46 − 1.38 to 4.26 0.307
De novo metastatic breast cancer 1.39 − 0.45 to 3.24 0.144
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Fig. 2  Cumulative incidence of non-severe + severe and severe cardio-
toxicity with respect to the number of relevant risk factors. Note Solid 
lines indicate cumulative incidence; dashed lines indicate correspond-
ing 95% CI of the cumulative incidence. For non-severe + severe car-
diotoxicity, the following risk factors were included: BMI > 30 kg/m2, 
smoking and cardiotoxicity during prior neoadjuvant/ adjuvant treat-
ment with trastuzumab and/or anthracyclines (Table 2). For severe car-
diotoxicity, the following risk factors were included: smoking, cardio-
toxicity during prior neoadjuvant/adjuvant treatment with trastuzumab 
and/or anthracyclines and baseline LVEF < 60% (Table 3)
Fig. 3  Swimmers plot of all patients who developed cardiotoxicity and received LVEF measurements thereafter (n = 74).
Breast Cancer Research and Treatment 
1 3
Conclusion
The cumulative incidence of severe cardiotoxicity in non-
smoking patients with a baseline LVEF above 60% who had 
no cardiotoxicity during prior neoadjuvant/adjuvant treat-
ment with trastuzumab and/or anthracycline after 4 years 
of trastuzumab treatment is low (3.1%). Therefore, serial 
cardiac monitoring can be omitted in these patients during 
long-term trastuzumab use.
Acknowledgements We thank Caroline Pauwels-Heemskerk for her 
assistance with identifying patients in the Netherlands Cancer Insti-
tute’s tumor registry and Jorine Rigterink for her assistance with col-
lecting data in the Netherlands Cancer Institute.
Author contributions JJEMK, MLB, AJT, PCJ, JCD, CH, CHS, GSS 
and AJ were involved in patient inclusion and data acquisition. NIB, 
TGS and HNR extracted the data from the electronic patient files. NIB, 
TGS, JR, MJMK, EB, GSS, MDL and AJ advised and performed the 
data analysis. NIB wrote the manuscript. All authors critically reviewed 
and approved the final manuscript.
Funding This study was funded by the Promotiefonds of the Albert 
Schweitzer Hospital, Dordrecht, The Netherlands and by Stichting A 
Sister’s Hope, and Stichting [Z]aan de Wandel. These foundations had 
no involvement in the conduct of the study.
Compliance with ethical standards 
Conflict of interest TGS received funding from Memidis Pharma out-
side the current project. GSS has received institutional research fund-
ing from AstraZeneca, Merck, Novartis and Roche. The other authors 
have no relevant financial or non-financial interests to disclose.
Ethical approval All procedures performed in this study involving 
human participants were in accordance with the ethical standard of 
the institutional and/or national research committee and with the 1964 
Helsinki Declaration and its later amendments or comparable ethical 
standards. This article does not contain any studies with animals per-
formed by any of the authors.
Informed consent Informed consent was waived by institutional review 
boards for this retrospective study.
Open Access This article is licensed under a Creative Commons 
Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, 
as long as you give appropriate credit to the original author(s) and the 
source, provide a link to the Creative Commons licence, and indicate 
if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons licence, unless 
indicated otherwise in a credit line to the material. If material is not 
included in the article’s Creative Commons licence and your intended 
use is not permitted by statutory regulation or exceeds the permitted 
use, you will need to obtain permission directly from the copyright 
holder. To view a copy of this licence, visit http://creat iveco mmons 
.org/licen ses/by/4.0/.
References 
 1. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, 
Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C et al 
(2005) Trastuzumab after adjuvant chemotherapy in HER2-posi-
tive breast cancer. N Engl J Med 353(16):1659–1672
 2. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, David-
son NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA et al (2005) 
Trastuzumab plus adjuvant chemotherapy for operable HER2-
positive breast cancer. N Engl J Med 353(16):1673–1684
 3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Baja-
monde A, Fleming T, Eiermann W, Wolter J, Pegram M et al 
(2001) Use of chemotherapy plus a monoclonal antibody against 
HER2 for metastatic breast cancer that overexpresses HER2. N 
Engl J Med 344(11):783–792
 4. Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes 
A, Herrmann J, Porter C, Lyon AR, Lancellotti P et al (2020) 
Management of cardiac disease in cancer patients throughout 
oncological treatment: ESMO consensus recommendations. Ann 
Oncol 31(2):171–190
 5. Petrelli F, Barni S (2013) A pooled analysis of 2618 patients 
treated with trastuzumab beyond progression for advanced breast 
cancer. Clin Breast Cancer 13(2):81–87
 6. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, 
Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S et al (2015) 
Pertuzumab, trastuzumab, and docetaxel in HER2-positive meta-
static breast cancer. N Engl J Med 372(8):724–734
 7. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess 
KR, Michaud LB, Gonzalez-Angulo AM, Hortobagyi GN, Esteva 
FJ (2006) Long-term cardiac tolerability of trastuzumab in meta-
static breast cancer: the M.D. Anderson Cancer Center experience. 
J Clin Oncol 24(25):4107–4115
 8. Rossi M, Carioli G, Bonifazi M, Zambelli A, Franchi M, Moja 
L, Zambon A, Corrao G, La Vecchia C, Zocchetti C et al (2016) 
Trastuzumab for HER2+ metastatic breast cancer in clinical prac-
tice: cardiotoxicity and overall survival. Eur J Cancer 52:41–49
 9. Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Den-
duluri N, Dent S, Douglas PS, Durand JB, Ewer M et al (2017) 
Prevention and monitoring of cardiac dysfunction in survivors of 
adult cancers: American Society of Clinical Oncology clinical 
practice guideline. J Clin Oncol 35(8):893–911
 10. Onitilo AA, Engel JM, Stankowski RV (2014) Cardiovascular 
toxicity associated with adjuvant trastuzumab therapy: preva-
lence, patient characteristics, and risk factors. Ther Adv Drug 
Saf 5(4):154–166
 11. Jawa Z, Perez RM, Garlie L, Singh M, Qamar R, Khandheria BK, 
Jahangir A, Shi Y (2016) Risk factors of trastuzumab-induced 
cardiotoxicity in breast cancer: a meta-analysis. Medicine (Balti-
more) 95(44):e5195
 12. Steenbruggen TG, Bouwer NI, Smorenburg CH, Rier HN, Jager 
A, Beelen K, ten Tije AJ, de Jong PC, Drooger JC, Holterhues C 
et al (2019) Radiological complete remission in HER2-positive 
metastatic breast cancer patients: what to do with trastuzumab? 
Breast Cancer Res Treat 178:597–605
 13. Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, 
Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon 
AR et al (2016) 2016 ESC position paper on cancer treatments 
and cardiovascular toxicity developed under the auspices of the 
ESC Committee for practice guidelines: the task force for cancer 
treatments and cardiovascular toxicity of the European Society of 
Cardiology (ESC). Eur Heart J 37(36):2768–2801
 14. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-
Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP et al 
(2014) Expert consensus for multimodality imaging evaluation 
of adult patients during and after cancer therapy: a report from 
 Breast Cancer Research and Treatment
1 3
the American Society of Echocardiography and the European 
Association of Cardiovascular Imaging. Eur Heart J Cardiovasc 
Imaging 15(10):1063–1093
 15. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins 
KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamer-
son KA, Jones DW et al (2018) 2017 ACC/AHA/AAPA/ABC/
ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the 
prevention, detection, evaluation, and management of high blood 
pressure in adults: a report of the american college of cardiol-
ogy/American Heart Association task force on clinical practice 
guidelines. J Am Coll Cardiol 71(19):e127–e248
 16. Durrleman S, Simon R (1989) Flexible regression models with 
cubic splines. Stat Med 8(5):551–561
 17. Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans 
P, Rutgers E, Zackrisson S, Cardoso F, Committee EG (2015) 
Primary breast cancer: ESMO clinical practice guidelines for 
diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v8-30
 18. Untch M, Muscholl M, Tjulandin S, Jonat W, Meerpohl HG, 
Lichinitser M, Manikhas AG, Coumbos A, Kreienberg R, du Bois 
A et al (2010) First-line trastuzumab plus epirubicin and cyclo-
phosphamide therapy in patients with human epidermal growth 
factor receptor 2-positive metastatic breast cancer: cardiac safety 
and efficacy data from the herceptin, cyclophosphamide, and epi-
rubicin (HERCULES) trial. J Clin Oncol 28(9):1473–1480
 19. Isabel B, Celia G, Francisco Javier M-P, Jose Manuel G, Fer-
nando R-S (2020) Predictor of trastuzumab-induced cardio-
toxicity in breast cancer (BC) patients: HER2/neu 655 poly-
morphisms, biochemical and clinical features. J Clin Oncol 
38(15_suppl):1033–1033
 20. Ho KK, Pinsky JL, Kannel WB, Levy D (1993) The epidemiology 
of heart failure: the Framingham Study. J Am Coll Cardiol 22(4 
Suppl A):6A-13A
 21. Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, 
Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, 
Bratland A, Storas TH et al (2016) Prevention of cardiac dysfunc-
tion during adjuvant breast cancer therapy (PRADA): a 2 × 2 fac-
torial, randomized, placebo-controlled, double-blind clinical trial 
of candesartan and metoprolol. Eur Heart J 37(21):1671–1680
 22. Lynce F, Barac A, Geng X, Dang C, Yu AF, Smith KL, Gallagher 
C, Pohlmann PR, Nunes R, Herbolsheimer P et al (2019) Prospec-
tive evaluation of the cardiac safety of HER2-targeted therapies 
in patients with HER2-positive breast cancer and compromised 
heart function: the SAFE-HEaRt study. Breast Cancer Res Treat 
175(3):595–603
 23. Nowsheen S, Aziz K, Park JY, Lerman A, Villarraga HR, Ruddy 
KJ, Herrmann J (2018) Trastuzumab in female breast cancer 
patients with reduced left ventricular ejection fraction. J Am Heart 
Assoc 7(15):e008637
 24. Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky 
MJ, Pagano JJ, Chow K, Thompson RB, Vos LJ et al (2017) Mul-
tidisciplinary approach to novel therapies in cardio-oncology 
research (MANTICORE 101-Breast): a randomized trial for the 
prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol 
35(8):870–877
 25. Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, 
McCaskill-Stevens W, Munster PN (2019) Randomized trial 
of lisinopril versus carvedilol to prevent trastuzumab car-
diotoxicity in patients with breast cancer. J Am Coll Cardiol 
73(22):2859–2868
 26. Bailey EA, Bailey DL (2012) Results from an Australian and New 
Zealand audit of left ventricular ejection fraction from gated heart 
pool scan analysis. Nucl Med Commun 33(1):102–111
 27. Huang H, Nijjar PS, Misialek JR, Blaes A, Derrico NP, Kazmirc-
zak F, Klem I, Farzaneh-Far A, Shenoy C (2017) Accuracy of 
left ventricular ejection fraction by contemporary multiple gated 
acquisition scanning in patients with cancer: comparison with 
cardiovascular magnetic resonance. J Cardiovasc Magn Reson 
19(1):34
 28. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, 
Pedrini JL, Pienkowski T, Knott A et al (2012) Pertuzumab plus 
trastuzumab plus docetaxel for metastatic breast cancer. N Engl J 
Med 366(2):109–119
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
Affiliations
N. I. Bouwer1,2  · T. G. Steenbruggen3 · J. van Rosmalen4 · H. N. Rier5 · J. J. E. M. Kitzen1 · M. L. van Bekkum6 · 
A. J. Ten Tije7 · P. C. de Jong8 · J. C. Drooger9 · C. Holterhues10 · C. H. Smorenburg3 · M. J. M. Kofflard2 · E. Boersma11 · 
G. S. Sonke3 · M.‑D. Levin1 · A. Jager5
1 Department of Internal Medicine, Albert Schweitzer 
Hospital, 3300 AK Dordrecht, South-Holland, 
The Netherlands
2 Department of Cardiology, Albert Schweitzer Hospital, 
Dordrecht, The Netherlands
3 Department of Medical Oncology, The Netherlands Cancer 
Institute, Amsterdam, The Netherlands
4 Department of Biostatistics, Erasmus MC, University 
Medical Centre Rotterdam, Rotterdam, The Netherlands
5 Department of Medical Oncology, Erasmus MC, Cancer 
Institute, Rotterdam, The Netherlands
6 Department of Medical Oncology, Reinier de Graaf Hospital, 
Delft, The Netherlands
7 Department of Medical Oncology, Amphia Hospital, Breda, 
The Netherlands
8 Department of Medical Oncology, Sint Antonius Hospital, 
Utrecht, The Netherlands
9 Department of Medical Oncology, Ikazia Hospital, 
Rotterdam, The Netherlands
10 Department of Medical Oncology, Haga Hospital, 
The Hague, The Netherlands
11 Department of Cardiology, Erasmus MC, University Medical 
Centre Rotterdam, Rotterdam, The Netherlands
